TOLERABILITY/PHARMACOKINETICS OF DAB389 IL 2 IN PATIENTS WITH SEVER PSORIASIS

这是一项开放标签、剂量递增的多中心试验，旨在确定 安全性、耐受性和药代动力学参数 DAB 389 IL-2在重度银屑病患者中的应用 剂量选择 因为之前的研究表明， 更频繁地在更高的剂量和有效性已经存在 剂量该方案探索了较低和多样化的治疗方案。 还将评估疗效。 将以剂量递增方式分配共计45例患者 3个剂量组之一（0.5、1.5和5.0 ug/kg/天）。 药物是 每隔一周给药3天，持续8周。

This is an open-label, dose-escalating multi-center trial to determine the safety, tolerability, and pharmacokinetic parameter of 3 does of DAB389IL-2 in patients with sever psoriasis. The doses were chosen because previous studies have domonstrated that adverse experiences occur more frequently at higher doses and efficacy has been present at all doses. This protocol explores and lower and varied treatment schedule. Efficacy will also be assessed. A total of forty-five patient will be assigned in a dose escalating manner to one of the 3 dose groups (0.5, 1.5, and 5.0 ug/kg/day). Drug is administered 3 day every other week for 8 weeks.